Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Mar-25-23 | Mar-26-22 | Mar-27-21 | Mar-28-20 | Mar-30-19 | Mar-31-18 | Mar-25-17 | Mar-26-16 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues: |
HPMS Products | 725.6 | 594.3 | 265.2 | | | | | |
India | 69.3 | 18.3 | 14.5 | | | | | |
Vietnam | 93.8 | 72.2 | 10.1 | | | | | |
High-Performance Mixed-Signal Products | | | | 171.2 | 144.7 | | | |
Other | 1,008.9 | 1,096.7 | 1,079.5 | 1,110.0 | 1,040.9 | | | |
Total revenues [+] | 1,897.6 | 1,781.5 | 1,369.2 | 1,281.1 | 1,185.5 | 1,532.2 | 1,538.9 | 1,169.3 |
Licensing | | | | | | | | -11.7 |
Products | 1,897.6 | 1,781.5 | 1,369.2 | 1,281.1 | 1,185.5 | 1,532.2 | | |
Revenue growth [+] | 6.5% | 30.1% | 6.9% | 8.1% | -22.6% | -0.4% | 31.6% | 27.6% |
HPMS Products | 22.1% | 124.1% | | | | | | |
India | 279.8% | 26.1% | | | | | | |
Vietnam | 29.9% | 613.4% | | | | | | |
High-Performance Mixed-Signal Products | | | | 18.3% | | | | |
Rest of World | 10.9% | 71.4% | 11.9% | 21.8% | | | | |
Cost of goods sold | 940.6 | 857.8 | 661.9 | 607.0 | 588.0 | 771.5 | 781.1 | 614.4 |
Gross profit | 957.0 | 923.6 | 707.3 | 674.2 | 597.5 | 760.7 | 757.8 | 554.8 |
Gross margin | 50.4% | 51.8% | 51.7% | 52.6% | 50.4% | 49.6% | 49.2% | 47.5% |
Selling, general and administrative | 153.1 | 151.0 | 127.0 | 131.1 | 126.5 | 131.8 | 127.3 | 117.1 |
Research and development | 458.4 | 406.3 | 342.8 | 347.6 | 375.1 | 366.4 | 303.7 | 269.2 |
Other operating expenses | | | | | 13.8 | | | -11.7 |
EBITDA [+] | 416.6 | 428.4 | 284.6 | 263.6 | 161.9 | 343.9 | 390.3 | 238.3 |
EBITDA growth | -2.7% | 50.5% | 8.0% | 62.8% | -52.9% | -11.9% | 63.8% | 46.0% |
EBITDA margin | 22.0% | 24.0% | 20.8% | 20.6% | 13.7% | 22.4% | 25.4% | 20.4% |
Depreciation | 37.5 | 33.1 | 32.6 | 39.9 | 32.0 | 27.7 | 26.0 | 22.4 |
EBITA | 379.1 | 395.3 | 252.0 | 223.7 | 129.9 | 316.2 | 364.3 | 215.9 |
EBITA margin | 20.0% | 22.2% | 18.4% | 17.5% | 11.0% | 20.6% | 23.7% | 18.5% |
Amortization of intangibles | 33.7 | 29.0 | 14.5 | 28.3 | 47.8 | 53.7 | 37.4 | 35.7 |
EBIT [+] | 345.4 | 366.3 | 237.5 | 195.4 | 82.1 | 262.5 | 326.9 | 180.2 |
EBIT growth | -5.7% | 54.2% | 21.6% | 138.0% | -68.7% | -19.7% | 81.4% | 40.4% |
EBIT margin | 18.2% | 20.6% | 17.3% | 15.3% | 6.9% | 17.1% | 21.2% | 15.4% |
Non-recurring items [+] | 96.4 | | 0.4 | 21.9 | -18.7 | | 9.8 | |
Asset impairment | 85.8 | | | | | | 9.8 | |
Restructuring charges | 10.6 | | 0.4 | 21.9 | | | | |
Loss (gain) on sale of assets | | | | | -4.9 | | | |
Pension curtailments and settlements | | | | | -13.8 | | | |
Interest income, net [+] | 9.1 | 0.6 | 5.2 | 9.4 | 7.0 | 3.6 | -1.9 | -2.4 |
Interest expense | 0.9 | 0.9 | 1.1 | 1.1 | 1.1 | 1.2 | 3.6 | 3.3 |
Interest income | 10.0 | 1.6 | 6.3 | 10.5 | 8.0 | 4.8 | 1.7 | 0.9 |
Other income (expense), net [+] | -3.4 | 1.7 | 2.8 | -1.6 | -14.0 | -1.0 | -0.1 | -1.8 |
Other | -3.4 | 1.7 | 2.8 | -1.6 | -0.2 | -1.0 | -0.1 | -1.8 |
Pre-tax income | 254.7 | 368.7 | 245.2 | 181.3 | 93.7 | 265.1 | 315.0 | 176.0 |
Income taxes | 78.0 | 42.3 | 27.9 | 21.8 | 3.8 | 103.1 | 53.8 | 52.4 |
Tax rate | 30.6% | 11.5% | 11.4% | 12.0% | 4.0% | 38.9% | 17.1% | 29.8% |
Net income | 176.7 | 326.4 | 217.3 | 159.5 | 90.0 | 162.0 | 261.2 | 123.6 |
Net margin | 9.3% | 18.3% | 15.9% | 12.4% | 7.6% | 10.6% | 17.0% | 10.6% |
|
Basic EPS [+] | $3.18 | $5.70 | $3.74 | $2.74 | $1.50 | $2.55 | $4.12 | $1.96 |
Growth | -44.2% | 52.3% | 36.8% | 82.7% | -41.4% | -38.1% | 110.8% | 121.6% |
Diluted EPS [+] | $3.09 | $5.52 | $3.62 | $2.64 | $1.46 | $2.46 | $3.92 | $1.87 |
Growth | -44.0% | 52.5% | 37.2% | 80.5% | -40.5% | -37.4% | 109.5% | 121.5% |
|
Shares outstanding (basic) [+] | 55.6 | 57.3 | 58.1 | 58.3 | 60.1 | 63.4 | 63.3 | 63.2 |
Growth | -2.9% | -1.4% | -0.4% | -3.0% | -5.2% | 0.1% | 0.2% | 1.1% |
Shares outstanding (diluted) [+] | 57.2 | 59.1 | 60.1 | 60.5 | 61.6 | 66.0 | 66.6 | 66.0 |
Growth | -3.2% | -1.5% | -0.7% | -1.8% | -6.6% | -0.9% | 0.9% | 1.2% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|